Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Thomas Povsic

Cardiovascular Disease Durham, NC Medical Doctor

NPI 1437233327 CMS profile 518114

2100 Erwin Rd, Durham, NC 27710

Open in the dashboard

General payments

$23,554

46 records reported · program years 2019–2024

Research payments

$197,100

Paid to them · 76 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$150,107 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Thomas Povsic of Durham, NC is reported in the CMS Open Payments database as having received $23,554 across 46 general payments and $197,100 in research payments paid to them. Separately, studies naming them as principal investigator received $150,107 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $24,975 9
2023 General $1,860 4
2023 Research $86,650 32
2022 General $4,688 7
2022 Research $85,350 34
2021 General $1,831 2
2021 Research $125 1
2019 General $15,175 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Povsic
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Thomas Povsic were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Thomas Povsic Cardiovascular Disease median Middle half National median
2019 $15,175 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $1,831 $335 $101–$1,037 $132
2022 $4,688 $395 $121–$1,211 $149
2023 $1,860 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. CSL Behring $7,965 32 payments
  2. Boehringer Ingelheim International GmbH $7,710 10 payments
  3. Eli Lilly and Company $7,210 1 payment
  4. AstraZeneca AB $556 1 payment
  5. Novo Nordisk Inc $82 1 payment
  6. Shockwave Medical, Inc $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $15,476 12 payments
  2. Travel and Lodging $6,236 15 payments
  3. Food and Beverage $1,843 19 payments
Products named General payments · program years 2019–2024
  1. Vascular Lithotripsy $31 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Novo Nordisk AS $197,100 76 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

394

Median for Interventional Cardiology: 2,236

Drug cost

$61,880

Median for Interventional Cardiology: $380,412

Branded share of claims

25.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 29 $23,238
Eliquis Apixaban Brand 22 $22,779
Xarelto Rivaroxaban Brand 20 $10,824
Ezetimibe Generic 54 $1,237
Rosuvastatin Calcium Generic 78 $1,087
Metoprolol Succinate Generic 43 $780
Nitroglycerin Patch Nitroglycerin Brand 12 $382
Pantoprazole Sodium Generic 15 $343
Carvedilol Generic 30 $273
Atorvastatin Calcium Generic 30 $268

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$8,953

Medicare's payments for the services billed

Medicare patients

64

Average age 77

Services billed

122

24 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 55%
Atrial fibrillation 39%
Chronic kidney disease 38%
Diabetes 36%
Heart failure 34%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record